Type 1 Diabetes
.gif){kind=logo}
Recently diagnosed with Type 1 Diabetes? Take action.
Learn more: teplizumab
Learn more: ClinicalTrials.gov
West Nile Virus
West Nile Virus Phase 2 clinical study.Learn more: ClinicalTrials.gov Learn more: MGAWN1
Partnering
MacroGenics is pursuing alliances to participate in development of its proprietary product candidates and technology platforms.
Learn moreCompany Highlights
- Robust pipeline in autoimmunity, oncology and infectious diseases
- Global partnership with Eli Lilly for development of teplizumab
- Fully-integrated biologics capabilities across product development process
- Strong financial position and blue-chip investor base
- Experienced management team and highly collaborative corporate culture
Home»Pipeline
Product Pipeline
MacroGenics has a diverse portfolio of product candidates with several clinical trials currently underway or planned for the near future. Set forth below is the company's development pipeline.
| Program (Target) | Indication | Lead Opt. | Pre-Clin. | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|
| AUTOIMMUNE | ||||||
| Teplizumab* (CD3) | Type 1 Diab. (PROTÉGÉ) | * | * | * | * | * |
| Pre-Diabetes (anticipated) | * | * | * | * | * | |
| Islet Transplantation | * | * | * | * | * | |
| 2nd Indication | * | * | * | * | * | |
| DART mAb (Undis.) | Inflammation | * | * | * | * | * |
| ONCOLOGY | ||||||
| MGAH22 (HER2) | Breast, other Solid Tumors | * | * | * | * | * |
| DART mAb (Undis.) | Multiple Solid Tumors | * | * | * | * | * |
| mAb (Undis.) | Multiple Solid Tumors | * | * | * | * | * |
| INFECTIOUS DISEASES | ||||||
| MGAWN1 | West Nile Virus | * | * | * | * | * |
| Various Pathogens | Smallpox, Dengue, H5N1 | * | * | * | * | * |